This article is more than 5 years old. Information may no longer be current.

Seven updates in neuro-oncology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The National Brain Tumor Society is calling for volunteers, patients, families, public policy advocates and physicians to act and join the society’s “brain tumor team” this month.

As a part of National Brain Tumor Awareness month, the society has promoted the annual campaign — this year titled “#BTAM = #BTeAM in 2017” — to raise awareness.

In conjunction with Brain Tumor Awareness Month, HemOnc Today presents seven updates within neuro-oncology.

• The addition of an investigational vaccine to chemotherapy led to unexpectedly longer survival for patients with glioblastoma, according to results of a small study published in Clinical Cancer Research. HemOnc Today spoke with Kristen Batich, MD, PhD, research scientist at Duke Cancer Institute, about the study results and their potential implications. Read more.
• The diagnosis of meningioma in childhood cancer survivors exposed to cranial radiotherapy increased risk for neurologic morbidity, according to a cohort study published in Journal of Clinical Oncology. Read more.
• NewYork-Presbyterian established the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma to conduct research and provide the latest treatments to patients with glioblastoma and other brain cancers. Read more.
• Radiation oncologists appear to lack consensus on whether stereotactic radiosurgery or whole-brain radiotherapy is the optimal treatment strategy for patients with more than three brain metastases. Further, stereotactic radiosurgery is used more frequently to treat brain metastases than is recommended in consensus guidelines. Read more.
• A wearable medical device designed to deliver alternating electrical fields administered in addition to temozolomide chemotherapy improved survival in patients with glioblastoma, according to results from the phase 3 EF-14 trial presented at the American Association for Cancer Research Annual Meeting. Read more.
• Ashley L. Sumrall, MD, and David L. Jennings II, MSN, RN, AGPCNP-BC, offered commentary on the Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, which featured data from key studies on targeted therapies and immunotherapies. Read more.
• The FDA granted orphan drug designation to epidermal growth factor receptor–targeted, doxorubicin-loaded EDV nanocells (EnGeneIC Dream Vector, EnGenicIC) — a first-in-class, cyto-immunotherapy technology designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system’s natural antitumor response — for the treatment of glioblastoma multiforme. Read more.